ERCC1 Expression Can Predict Response to Platinum-Based Induction Chemotherapy in Head and Neck Cancer Cases |
Ameri, Ahmad
(Department of Clinical Oncology, Shahid Beheshti University of Medical Sciences)
Mortazavi, Nafiseh (Department of Pathology, Shahid Beheshti University of Medical Sciences) Ahmadi, Helaleh Khoshbakht (Department of Clinical Oncology, Shahid Beheshti University of Medical Sciences) Novin, Kambiz (Department of Clinical Oncology, Shahid Beheshti University of Medical Sciences) |
1 | Alvarenga LM, Ruiz MT, Pavarino-Bertelli EC, et al (2008). Epidemiologic evaluation of head and neck patients in a university hospital of Northwestern Sao Paulo State. Braz J Otorhinolaryngol, 74, 68-73. DOI |
2 | Argiris A (2005). Induction chemotherapy for head and neck cancer: will history repeat itself. J Natl Compr Canc Netw, 3, 393-403. DOI |
3 | Bauman JE, Austin MC, Schmidt R, et al (2013). ERCC1 is a prognostic biomarker in locally advanced head and neck cancer: results from a randomised, phase II trial. Br J Cancer, 109, 2096-105. DOI |
4 | Bohanes P, Labonte MJ, Lenz HJ (2011). A review of excision repair cross-complementation group 1 in colorectal cancer. Clin Colorectal Cancer, 10, 157-64. DOI |
5 | Brockstein B, Haraf DJ, Rademaker AW, et al (2004). Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol, 15, 1179-86. DOI |
6 | Carey TE, Prince MEP (2015). Molecular Biology of Head and Neck Cancers. In 'Cancer principle and practice of oncology', Devita VT, Hellman S, Rosenberg SA. 10th ed. Wolters Kluwer, Philadelphia , 416-21. |
7 | Chen S, Zhang J, Wang R, Luo X, Chen H (2010). The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer, 70, 63-70. DOI |
8 | Cohen EE, Karrison TG, Kocherginsky M, et al (2014). Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer. Cancer Clin. Trials, 32, 2735-43. |
9 | Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008. Int J Cancer, 127, 2893-917. DOI |
10 | Fountzilas G, Bamias A, Kalogera-Fountzila A, et al (2009). Induction chemotherapy with docetaxel and cisplatin followed by concomitant chemoradiotherapy in patients with inoperable non-nasopharyngeal carcinoma of the head and neck. Anticancer Res, 29, 529-38. |
11 | Fountzilas G, Kalogera-Fountzila A, Lambaki S, et al (2009). MMP9 but not EGFR, MET, ERCC1, P16, and P-53 is associated with response to concomitant radiotherapy, cetuximab, and weekly cisplatin in patients with locally advanced head and neck cancer. J Oncol, 2009, 305908. |
12 | Gossage L, Madhusudan S (2007). Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev, 33, 565-77. DOI |
13 | Handra-Luca A, Hernandez J, Mountzios G, et al (2007). Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res, 13, 3855-9. DOI |
14 | Hayes M, Lan C, Yan J, et al (2011). ERCC1 expression and outcomes in head and neck cancer treated with concurrent cisplatin and radiation. Anticancer Res, 31, 4135-9. |
15 | Hitt R, Grau JJ, Lopez-Pousa A, et al (2013). A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol, 25, 216-25. |
16 | Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. DOI |
17 | Jun HJ, Ahn MJ, Kim HS, et al (2008). ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer, 99, 167-72. DOI |
18 | Li FY, Ren XB, Xie XY, Zhang J (2013). Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum-based chemotherapy in ovarian cancer. Asian Pac J Cancer Prev, 14, 7203-6. DOI |
19 | Koh Y, Kim TM, Jeon YK, et al (2009). Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. Ann Oncol, 20, 1414-9. DOI |
20 | Langer CJ (2012). Exploring biomarkers in head and neck cancer. Cancer, 118, 3882-92. DOI |
21 | Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2-CT method. Methods, 25, 402-8. DOI |
22 | Ragin CC, Modugno F, Gollin SM (2007). The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res, 86, 104-14. DOI |
23 | Vilmar A, Sorensen JB (2009). Excision repair cross complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer, 64, 131-9. DOI |
24 | Zamble DB, Mu D, Reardon JT, et al (1996). Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry, 35, 10004-13. DOI |
25 | Zhong LP, Zhang CP, Ren GX, et al (2012). Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol, 48, 1076-84. |